GEN1029 (HexaBody-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

NIAID Data Ecosystem2026-03-10 收录

肿瘤药物临床试验

DR5死亡受体

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2276842 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody-DR5/DR5) in a mixed population of patients with specified solid tumors

创建时间：

2018-04-15

BMS-247550 in Treating Patients With Advanced Cancers

肿瘤药物临床试验

肿瘤机制研究

Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing

NIAID Data Ecosystem50

Supplementary Material for: Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

乳腺癌新辅助治疗

肿瘤药物临床试验

Background: Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, ‘SOFIA'. Patients and Methods: Inc

Figshare2017-06-20 更新30

Dataset from A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma

软组织肉瘤

肿瘤药物临床试验

The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.

NIAID Data Ecosystem10

Supplementary Material for: Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma After Progression on Atezolizumab Plus Bevacizumab (REGONEXT)

肝细胞癌治疗

肿瘤药物临床试验

Introduction: Atezolizumab-bevacizumab (Atezo-Bev) has become the standard first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, data on subsequent treatment af

DataCite Commons2025-01-20 更新40

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

前列腺癌联合治疗

肿瘤药物临床试验

Background: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with

DataMed20

GEN1029 (HexaBody-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

资源简介：

相关数据集